Kathleen Olivas

Title: Innovations by Kathleen Olivas

Introduction

Kathleen Olivas is a prominent inventor based in Tacoma, WA (US). She has made significant contributions to the field of biomedical research, particularly in the development of targeted therapies for diseases such as cancer and autoimmune disorders. With a total of 2 patents, her work is paving the way for innovative treatment options.

Latest Patents

Kathleen's latest patents include groundbreaking compounds and compositions that focus on the nicotinamide adenine dinucleotide salvage pathway. One of her patents, titled "Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates," describes compounds where a NAMPT Drug Unit is conjugated to a targeting Ligand Unit. This innovative approach allows for the targeted delivery of NAMPT inhibitor compounds at the site of action, which is crucial for treating diseases characterized by abnormal cells, such as cancer or autoimmune diseases. Another patent, "Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors," further explores similar concepts, emphasizing the importance of targeted therapies in modern medicine.

Career Highlights

Kathleen Olivas is currently associated with Seagen Inc., a company known for its focus on developing innovative cancer therapies. Her work at Seagen has allowed her to collaborate with leading experts in the field, enhancing the impact of her research.

Collaborations

Some of her notable coworkers include Christopher Scott Neumann and Kung-Pern Wang. Their collaborative efforts contribute to the advancement of targeted therapies and the overall mission of Seagen Inc.

Conclusion

Kathleen Olivas is a trailblazer in the field of biomedical innovation, with her patents reflecting a commitment to improving treatment options for serious diseases. Her work continues to inspire advancements in targeted therapies, making a significant impact on patient care.